European Biomedical Institute

🌎 For manufacturers selling internationally, navigating FDA and MDR biocompatibility requirements is a major challenge.

EU MDR follows ISO 10993-1’s risk-based framework, emphasizing chemical characterization and justifying the testing approach. The FDA often requests more in vivo data and has specific guidance on toxicity endpoints, such as systemic toxicity and sensitization.

Understanding the differences is key:

👉 Where do standards converge and diverge?
👉 How to leverage chemical characterization and extractables & leachables data to minimize animal testing and satisfy both agencies?
👉 What are the documentation differences, particularly for Biological Evaluation Reports?

EBI guides manufacturers through these nuances, helping build integrated strategies that anticipate and address regulatory questions proactively.

🚀 Selling across both markets? Let’s discuss a strategic approach bridging these regulatory frameworks.

hasztag hasztag hasztag hasztag hasztag hasztag

Grateful for an Unforgettable Arab Health Exhibition 2025

Now that the dust has settled, we want to take a moment to express our deepest gratitude to the organizers, participants, and everyone who made Arab Health Exhibition 2025 an unforgettable event. 🌟

The experience was nothing short of amazing—filled with inspiring conversations, cutting-edge innovations, and a shared passion for advancing global healthcare. We’re truly honored to have been part of this incredible journey.

A heartfelt thank you to everyone who connected with the EBI and NABI teams. Your enthusiasm and insights inspire us to keep striving for excellence. Until we meet again, Dubai! 🌍